John Abramson, MD, MSc, was family physician for more than 20 years. He is now a Lecturer in Healthcare Policy at Harvard Medical School and serves as a consultant to plaintiffs’ attorneys in litigation involving pharmaceuticals and medical devices, including cases involving statins.
Cholesterol-lowering statin therapy for healthy people is not as simple as 'yes' or 'no'Subscription
Recent reports of large trials extolling the virtues of statins have led many to believe that low-risk patients should take them, but an examination of the evidence provides food for thought.
With publication of the review article in The Lancet on 8 September 2016 looking at the efficacy and safety of statin therapy, the pressure on GPs to prescribe high-intensity statins to low-risk people has become even greater. Under the heading ‘Proven beneficial effects of statin therapy’, the review states: “Lowering low-density lipoprotein (LDL) cholesterol by 2mmol/L with an effective statin regimen for about five years in 10,000 patients would typically prevent major vascular ev
Prescribing statins: time to rein it inSubscription
Statins have been overprescribed for decades for many different reasons. Now is the time to reverse the trend.